1. **Value Line’s Ranks**—the rank for Timeliness; the rank for Safety; the Technical rank. Beta, the stock’s sensitivity to fluctuations of the market as a whole, is included in this box, but is not a rank. *(See Glossary for Industry rank.)*

2. **The Legends Box** contains the “cash flow” multiple, the amounts and dates of recent stock splits, and an indication if options on the stock are traded.

3. **Monthly price ranges of the stock**—plotted on a ratio (logarithmic) grid to show percentage changes in true proportion. For example, a ratio chart equalizes the move of a $10 stock that rises to $11 with that of a $100 stock that rises to $110. Both have advanced 10% and over the same space on a ratio grid.

4. The “Cash Flow” line—reported earnings plus depreciation (“cash flow”) multiplied by a number selected to correlate the stock’s 3- to 5-year projected target price, with ‘cash flow’ projected out to 2010.

5. **Recent Price**—see page 2 of the **Summary & Index** for the date, just under “Index to Stocks.”

6. **P/E ratio**—the recent price divided by the latest six months’ earnings per share plus earnings estimated for the next six months.

7. **Trailing and Median P/E**—the first is the recent price divided by the sum of reported earnings for the past 4 quarters; the second is an average of the price/earnings ratios over the past 10 years.

8. **Relative P/E ratio**—the stock’s current P/E divided by the median P/E for all stocks under Value Line review.

9. **The stock’s highest and lowest price of the year.**

10. **Dividend Yield**—cash dividends estimated to be declared in the next 12 months divided by the recent price.

11. **Target Price Range**—the range in which a stock price is likely to trade in the years 2012-14. Also shown in the “Projections” box on the left.

12. **Relative Price Strength** describes the stock’s past price performance relative to the Value Line (Arithmetic) Average of approximately 1,700 stocks. (A rising line indicates the stock price has been rising more than the Value Line universe.)

13. **The % Total Return** shows the price appreciation and dividends of a stock and the Value Line (Arithmetic) Index for the past 1, 3, and 5 years.

14. **The percent of shares traded monthly**—the number of shares traded each month as a % of the total outstanding.

15. **Statistical Array**—Value Line estimates appearing in the area on the right side are in **bold italics.**

16. **Business Data**—a brief description of the company’s business and major products along, with other important data.

17. **Analyst’s Commentary**—A 300-400-word report on recent developments and prospects—issued every three months on a preset schedule.

18. **The expected date of receipt by subscribers.** *The Survey* is mailed on a schedule that aims for delivery to every subscriber on Friday afternoon.


20. **Footnotes** explain a number of things, such as the way earnings are reported, whether basic or diluted.

21. **Quarterly Dividends Paid** are actual payments. The total of dividends paid in four quarters may not equal the figure shown in the annual series on dividends declared in the Statistical Array. (Sometimes a dividend declared at the end of the year will be paid in the first quarter of the following year.)

22. **Quarterly Sales** are shown on a gross basis. **Quarterly earnings** on a per-share basis (estimates in bold type).

23. **Annual Rates of Change** (on a compound per-share basis). Actual for each of the past 5 and 10 years, estimated for the next 3 to 5 years.

24. **Current Position**—total current assets and total current liabilities, and their detail.

25. **The Capital Structure** as of the indicated recent date showing, among other things, the $ amount and % of capital in long-term debt and preferred stock. We also show the number of times that interest charges were earned.


27. **Stock purchases/sales by institutions**—the number of times institutions with more than $100 million of assets under management bought or sold stock during the past three quarters and the total number of shares held by those institutions at the end of each quarter.

28. **The record of insider decisions**—the number of times officers and directors bought or sold stock or exercised options during the past nine months.

29. **The projected stock price** in 2012-14. Also, the total expected % gain/loss before dividends and the Annual Total Return (% including dividends).
JOHNSON & JOHNSON

RECENT PRICE 55.89

12.3

RELATIVE PE RATIO 0.84

TODAY 3.5%

VALUE LINE

LONG-TERM GROWTH PROSPECTS ARE BROAD BASED.

Three catalysts behind our forecast of earnings growth: advances of 8%, on average, in the 3 to 5 years subsequent to 2009 are J&J's ongoing acquisition program, expansion opportunities in emerging markets, and its promising late-stage pharmaceutical pipeline. Thanks to the first factor, which is funded by free cash flow running at $7.5 billion, J&J recently acquired Mentor, as well as Omrix Biopharmaceuticals and several foreign-based firms. Their medical expertise has enhanced the company's sizable R&D program.

This good-newsomics should be likely to outpace the market averages over the coming six to 12 months. Also, on a risk-adjusted basis, it offers attractive total return potential to 2012-2014.

David R. Cohen

May 29, 2009

BUSINESS: Johnson & Johnson manufactures and sells health care products. Major lines by segment: Consumer (baby care, non-prescription drugs, sanitary protection, and skin care), Med. Device & Diag. (wound closures, minimally invasive surgical instruments, diagnostics, orthopedics, and contact lenses), and Pharmaceutical (corticosteroids, psychiatric, anti-infective, and dermatological drugs). 2008 sales (operating income) by segment: Pharm., 39% (35%); Med. Device & Diag., 41% (36%); Consumer, 25% (15%).

J&J announced last week that its medical expertise has enhanced the company's sizable R&D program. Three catalysts behind our forecast of earnings growth: advances of 8%, on average, in the 3 to 5 years subsequent to 2009 are J&J's ongoing acquisition program, expansion opportunities in emerging markets, and its promising late-stage pharmaceutical pipeline. Thanks to the first factor, which is funded by free cash flow running at $7.5 billion, J&J recently acquired Mentor, as well as Omrix Biopharmaceuticals and several foreign-based firms. Their medical expertise has enhanced the company's sizable R&D program.

This good-newsomics should be likely to outpace the market averages over the coming six to 12 months. Also, on a risk-adjusted basis, it offers attractive total return potential to 2012-2014.

David R. Cohen

May 29, 2009

BUSINESS: Johnson & Johnson manufactures and sells health care products. Major lines by segment: Consumer (baby care, non-prescription drugs, sanitary protection, and skin care), Med. Device & Diag. (wound closures, minimally invasive surgical instruments, diagnostics, orthopedics, and contact lenses), and Pharmaceutical (corticosteroids, psychiatric, anti-infective, and dermatological drugs). 2008 sales (operating income) by segment: Pharm., 39% (35%); Med. Device & Diag., 41% (36%); Consumer, 25% (15%).

J&J announced last week that its medical expertise has enhanced the company's sizable R&D program. Three catalysts behind our forecast of earnings growth: advances of 8%, on average, in the 3 to 5 years subsequent to 2009 are J&J's ongoing acquisition program, expansion opportunities in emerging markets, and its promising late-stage pharmaceutical pipeline. Thanks to the first factor, which is funded by free cash flow running at $7.5 billion, J&J recently acquired Mentor, as well as Omrix Biopharmaceuticals and several foreign-based firms. Their medical expertise has enhanced the company's sizable R&D program.

This good-newsomics should be likely to outpace the market averages over the coming six to 12 months. Also, on a risk-adjusted basis, it offers attractive total return potential to 2012-2014.

David R. Cohen

May 29, 2009
TAKE ADVANTAGE OF OUR INTERNET SITE!

www.valueline.com

Value Line's Web site contains a wealth of information, including:

✔ stock market commentary three times a day
✔ stock prices
✔ stock price charts
✔ company news
✔ educational features

THERE IS ALSO MUCH MORE INFORMATION FOR SUBSCRIBERS TO The Value Line Investment Survey

Officers, directors, employees and affiliates of Value Line, Inc. ("VLI"), and Value Line's investment-management affiliate, EULAV Asset Management, LLC ("EULAV"), a wholly-owned subsidiary of Value Line, Inc., the parent company of Value Line Publishing, Inc. ("VLPI"), may hold stocks that are reviewed or recommended in this publication. EULAV also manages investment companies and other accounts that use the rankings and recommendations in this publication as part of their investment strategies. These accounts, as well as the officers, directors, employees and affiliates of VLI, may dispose of a security notwithstanding the fact that The Value Line Investment Survey (the “Survey”) ranks the issuer favorably; conversely, such accounts or persons may purchase or hold a security that is poorly ranked by the Survey. Some of the investment companies managed by EULAV only hold securities with a specified minimum Timeliness Rank by the Survey and dispose of those positions when the Timeliness Rank declines or is suspended. Subscribers to the Survey and its related publications as well as some institutional customers of VLPI will have access to the entire Value Line Investment Survey at 8:00 AM each Monday (or the next business day after a Monday when the New York Stock Exchange is closed). At the same time, portfolio managers for EULAV will receive reports providing Timeliness Ranking information. EULAV’s portfolio managers also may have access to publicly available information that may ultimately result in or influence a change in rankings or recommendations, such as earnings releases, changes in market value or disclosure of corporate transactions. The investment companies or accounts may trade upon such information prior to a change in ranking. While the rankings in the Survey are intended to be predictive of future relative performance of an issuer's securities, the Survey is not intended to constitute a recommendation of any specific security. Any investment decision with respect to any issuer covered by the Survey should be made as part of a diversified portfolio of equity securities and in light of an investor’s particular investment objectives and circumstances.